EA201390695A1 - Способы лечения рака - Google Patents

Способы лечения рака

Info

Publication number
EA201390695A1
EA201390695A1 EA201390695A EA201390695A EA201390695A1 EA 201390695 A1 EA201390695 A1 EA 201390695A1 EA 201390695 A EA201390695 A EA 201390695A EA 201390695 A EA201390695 A EA 201390695A EA 201390695 A1 EA201390695 A1 EA 201390695A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
tumors
treating cancer
ovarian
platinum
Prior art date
Application number
EA201390695A
Other languages
English (en)
Other versions
EA026168B1 (ru
Inventor
Джозеф Ананд Редди
Кристофер Пол Лимон
Original Assignee
Эндосайт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эндосайт, Инк. filed Critical Эндосайт, Инк.
Publication of EA201390695A1 publication Critical patent/EA201390695A1/ru
Publication of EA026168B1 publication Critical patent/EA026168B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны способы и композиции для лечения эпителиальных опухолей конъюгатом фолата-барвинка в комбинации по меньшей мере с одним другим химиотерапевтическим средством, где опухоли включают рак яичника, эндометрия или немелкоклеточный рак легких, включая устойчивые к платине опухоли яичника и чувствительные к платине опухоли яичника.
EA201390695A 2010-11-12 2011-11-11 Способы лечения рака EA026168B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41327510P 2010-11-12 2010-11-12
PCT/US2011/060407 WO2012065085A1 (en) 2010-11-12 2011-11-11 Methods of treating cancer

Publications (2)

Publication Number Publication Date
EA201390695A1 true EA201390695A1 (ru) 2013-12-30
EA026168B1 EA026168B1 (ru) 2017-03-31

Family

ID=46048353

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201390694A EA025069B1 (ru) 2010-11-12 2011-11-11 Способ и набор для лечения рака
EA201390695A EA026168B1 (ru) 2010-11-12 2011-11-11 Способы лечения рака

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201390694A EA025069B1 (ru) 2010-11-12 2011-11-11 Способ и набор для лечения рака

Country Status (16)

Country Link
US (3) US8987281B2 (ru)
EP (2) EP2638397A4 (ru)
JP (2) JP2013542263A (ru)
KR (2) KR20130140032A (ru)
CN (2) CN103282777A (ru)
AU (2) AU2011325982C1 (ru)
BR (2) BR112013011659A2 (ru)
CA (2) CA2817223A1 (ru)
CL (2) CL2013001324A1 (ru)
EA (2) EA025069B1 (ru)
HK (1) HK1189272A1 (ru)
IL (2) IL226246A0 (ru)
MX (2) MX2013005196A (ru)
SG (2) SG190245A1 (ru)
WO (2) WO2012065085A1 (ru)
ZA (2) ZA201304225B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
AU2011325982C1 (en) 2010-11-12 2015-08-20 Endocyte, Inc. Methods of treating cancer
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
US11162937B2 (en) 2013-11-19 2021-11-02 Purdue Research Foundation Patient selection method for inflammation
CN106132438B (zh) 2014-02-21 2020-03-03 尼克塔治疗印度私人有限公司 与抗CTLA-4抗体或抗PD-1抗体组合的IL-2Rβ选择性激动剂
CN103816548A (zh) * 2014-03-11 2014-05-28 北京林业大学 靶向亲水性聚合物-雷公藤甲素结合物
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
US20170035894A1 (en) * 2014-04-14 2017-02-09 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
EP3826613A4 (en) * 2018-08-31 2022-05-04 Sun Pharmaceutical Industries Limited PARENTERAL DOSAGE FORM OF CARBOPLATIN

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
DE60326833D1 (de) * 2002-05-15 2009-05-07 Endocyte Inc Vitamin-mitomycin-konjugate
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
SI1592457T1 (sl) 2003-01-27 2012-12-31 Endocyte, Inc. Konjugat folat-vinblastin kot zdravilo
RU2007139912A (ru) * 2005-03-30 2009-05-10 Пердью Рисерч Фаундейшн (Us) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
WO2007022493A2 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Ligand conjugates of vinca alkaloids, analogs, and derivatives
US20070065449A1 (en) * 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CA2737496A1 (en) * 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
CN102549434A (zh) * 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
AU2011325982C1 (en) 2010-11-12 2015-08-20 Endocyte, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
EP2638395A4 (en) 2016-06-01
SG190245A1 (en) 2013-06-28
CL2013001324A1 (es) 2014-05-16
MX2013005196A (es) 2013-06-28
KR20130140033A (ko) 2013-12-23
AU2011325982A1 (en) 2013-04-18
AU2011325982B2 (en) 2014-10-09
IL226247A0 (en) 2013-06-27
HK1189272A1 (zh) 2014-05-30
AU2011325989A1 (en) 2013-04-11
US8987281B2 (en) 2015-03-24
EA026168B1 (ru) 2017-03-31
BR112013011659A2 (pt) 2016-08-02
EP2638397A1 (en) 2013-09-18
AU2011325989B2 (en) 2014-10-09
KR20130140032A (ko) 2013-12-23
CN103282777A (zh) 2013-09-04
AU2011325982C1 (en) 2015-08-20
JP2013542263A (ja) 2013-11-21
BR112013011590A2 (pt) 2019-09-24
SG190244A1 (en) 2013-06-28
WO2012065085A1 (en) 2012-05-18
US20140066383A1 (en) 2014-03-06
CA2817223A1 (en) 2012-05-18
EA025069B1 (ru) 2016-11-30
EP2638397A4 (en) 2016-06-01
ZA201304225B (en) 2018-05-30
WO2012065079A4 (en) 2012-07-12
EA201390694A1 (ru) 2013-12-30
CL2013001322A1 (es) 2014-03-28
AU2011325989C1 (en) 2015-04-23
US20120122893A1 (en) 2012-05-17
ZA201304226B (en) 2017-11-29
EP2638395A1 (en) 2013-09-18
WO2012065079A1 (en) 2012-05-18
WO2012065085A4 (en) 2012-07-12
US20130330326A1 (en) 2013-12-12
CN103403552B (zh) 2016-01-06
MX2013005194A (es) 2013-06-28
JP2013542264A (ja) 2013-11-21
US8883737B2 (en) 2014-11-11
CN103403552A (zh) 2013-11-20
IL226246A0 (en) 2013-07-31
CA2817219A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
EA201390694A1 (ru) Способы лечения рака
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
BR112015009752A2 (pt) conjugados de anticorpo/fármaco e métodos de uso
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
WO2012103355A3 (en) Methods of detecting lung cancer
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
TR201910662T4 (tr) Pirrolobenzodiazepinler ve bunlara ait konjugatlar.
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
WO2011087845A3 (en) Metabolomic profiling of prostate cancer
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
MX340453B (es) Biomarcadores para cancer de pulmon.
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
WO2013036543A3 (en) Molecular imaging of cancer cells in vivo
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
MX2021005963A (es) Caracterizacion de adn metilado, arn y proteinas en la deteccion de neoplasia pulmonar.
BR112013006331A2 (pt) composições de fulvestranto e métodos de uso
WO2011106709A3 (en) Epithelial biomarkers for cancer prognosis
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
WO2018013531A8 (en) AUTO-ANTIBODY BIOMARKERS FOR THE EARLY DETECTION OF OVARIAN CANCER
TNSN08401A1 (en) Methods of treating diagnosing or detecting cancer
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
BR112014001979A2 (pt) uso do anticorpo i-3859 para a detecção e diagnóstico de câncer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU